Literature DB >> 34597124

A reservoir of stem-like CD8+ T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response.

Kelli A Connolly1, Manik Kuchroo2, Aarthi Venkat3, Achia Khatun4, Jiawei Wang3, Ivana William1, Noah I Hornick1, Brittany L Fitzgerald1, Martina Damo1, Moujtaba Y Kasmani4, Can Cui1, Eric Fagerberg1, Isabel Monroy1, Amanda Hutchins1, Julie F Cheung1, Gena G Foster1, Dylan L Mariuzza1, Mursal Nader1, Hongyu Zhao5, Weiguo Cui4,6, Smita Krishnaswamy7, Nikhil S Joshi1.   

Abstract

“Stem-like” TCF1+ CD8+ T (TSL) cells are necessary for long-term maintenance of T cell responses and the efficacy of immunotherapy, but, as tumors contain signals that should drive T cell terminal differentiation, how these cells are maintained in tumors remains unclear. In this study, we found that a small number of TCF1+ tumor-specific CD8+ T cells were present in lung tumors throughout their development. Yet, most intratumoral T cells differentiated as tumors progressed, corresponding with an immunologic shift in the tumor microenvironment (TME) from “hot” (T cell inflamed) to “cold” (non–T cell inflamed). By contrast, most tumor-specific CD8+ T cells in tumor-draining lymph nodes (dLNs) had functions and gene expression signatures similar to TSL from chronic lymphocytic choriomeningitis virus infection, and this population was stable over time despite the changes in the TME. dLN T cells were the developmental precursors of, and were clonally related to, their more differentiated intratumoral counterparts. Our data support the hypothesis that dLN T cells are the developmental precursors of the TCF1+ T cells in tumors that are maintained by continuous migration. Last, CD8+ T cells similar to TSL were also present in LNs from patients with lung adenocarcinoma, suggesting that a similar model may be relevant in human disease. Thus, we propose that the dLN TSL reservoir has a critical function in sustaining antitumor T cells during tumor development and in protecting them from the terminal differentiation that occurs in the TME.

Entities:  

Mesh:

Year:  2021        PMID: 34597124      PMCID: PMC8593910          DOI: 10.1126/sciimmunol.abg7836

Source DB:  PubMed          Journal:  Sci Immunol        ISSN: 2470-9468


  107 in total

1.  RANTES production by memory phenotype T cells is controlled by a posttranscriptional, TCR-dependent process.

Authors:  Bradley J Swanson; Masaaki Murakami; Thomas C Mitchell; John Kappler; Philippa Marrack
Journal:  Immunity       Date:  2002-11       Impact factor: 31.745

2.  Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor.

Authors:  Nikhil S Joshi; Weiguo Cui; Anmol Chandele; Heung Kyu Lee; David R Urso; James Hagman; Laurent Gapin; Susan M Kaech
Journal:  Immunity       Date:  2007-08       Impact factor: 31.745

3.  Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.

Authors:  Stefani Spranger; Daisy Dai; Brendan Horton; Thomas F Gajewski
Journal:  Cancer Cell       Date:  2017-05-08       Impact factor: 31.743

4.  The differential effects of mutant p53 alleles on advanced murine lung cancer.

Authors:  Erica L Jackson; Kenneth P Olive; David A Tuveson; Roderick Bronson; Denise Crowley; Michael Brown; Tyler Jacks
Journal:  Cancer Res       Date:  2005-11-15       Impact factor: 12.701

Review 5.  Elements of cancer immunity and the cancer-immune set point.

Authors:  Daniel S Chen; Ira Mellman
Journal:  Nature       Date:  2017-01-18       Impact factor: 49.962

6.  Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy.

Authors:  Simon Turcotte; Alena Gros; Katherine Hogan; Eric Tran; Christian S Hinrichs; John R Wunderlich; Mark E Dudley; Steven A Rosenberg
Journal:  J Immunol       Date:  2013-07-31       Impact factor: 5.422

7.  High-dimensional single cell analysis identifies stem-like cytotoxic CD8+ T cells infiltrating human tumors.

Authors:  Jolanda Brummelman; Emilia M C Mazza; Giorgia Alvisi; Federico S Colombo; Andrea Grilli; Joanna Mikulak; Domenico Mavilio; Marco Alloisio; Francesco Ferrari; Egesta Lopci; Pierluigi Novellis; Giulia Veronesi; Enrico Lugli
Journal:  J Exp Med       Date:  2018-08-28       Impact factor: 14.307

8.  TOX is a critical regulator of tumour-specific T cell differentiation.

Authors:  Andrew C Scott; Friederike Dündar; Paul Zumbo; Smita S Chandran; Christopher A Klebanoff; Mojdeh Shakiba; Prerak Trivedi; Laura Menocal; Heather Appleby; Steven Camara; Dmitriy Zamarin; Tyler Walther; Alexandra Snyder; Matthew R Femia; Elizabeth A Comen; Hannah Y Wen; Matthew D Hellmann; Niroshana Anandasabapathy; Yong Liu; Nasser K Altorki; Peter Lauer; Olivier Levy; Michael S Glickman; Jonathan Kaye; Doron Betel; Mary Philip; Andrea Schietinger
Journal:  Nature       Date:  2019-06-17       Impact factor: 49.962

9.  A mouse model for the study of anti-tumor T cell responses in Kras-driven lung adenocarcinoma.

Authors:  Brittany Fitzgerald; Kelli A Connolly; Can Cui; Eric Fagerberg; Dylan L Mariuzza; Noah I Hornick; Gena G Foster; Ivana William; Julie F Cheung; Nikhil S Joshi
Journal:  Cell Rep Methods       Date:  2021-09-16

10.  Chromatin states define tumour-specific T cell dysfunction and reprogramming.

Authors:  Mary Philip; Lauren Fairchild; Liping Sun; Ellen L Horste; Steven Camara; Mojdeh Shakiba; Andrew C Scott; Agnes Viale; Peter Lauer; Taha Merghoub; Matthew D Hellmann; Jedd D Wolchok; Christina S Leslie; Andrea Schietinger
Journal:  Nature       Date:  2017-05-17       Impact factor: 49.962

View more
  30 in total

Review 1.  TCR-sequencing in cancer and autoimmunity: barcodes and beyond.

Authors:  Kristen E Pauken; Kaitlyn A Lagattuta; Benjamin Y Lu; Liliana E Lucca; Adil I Daud; David A Hafler; Harriet M Kluger; Soumya Raychaudhuri; Arlene H Sharpe
Journal:  Trends Immunol       Date:  2022-01-25       Impact factor: 16.687

Review 2.  Fate-mapping mice: new tools and technology for immune discovery.

Authors:  Scarlett E Lee; Brian D Rudd; Norah L Smith
Journal:  Trends Immunol       Date:  2022-01-31       Impact factor: 16.687

3.  Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses.

Authors:  Can Cui; Jiawei Wang; Eric Fagerberg; Ping-Min Chen; Kelli A Connolly; Martina Damo; Julie F Cheung; Tianyang Mao; Adnan S Askari; Shuting Chen; Brittany Fitzgerald; Gena G Foster; Stephanie C Eisenbarth; Hongyu Zhao; Joseph Craft; Nikhil S Joshi
Journal:  Cell       Date:  2021-11-30       Impact factor: 41.582

4.  Cutting Edge: Promoting T Cell Factor 1+ T Cell Self-Renewal to Improve Programmed Cell Death Protein 1 Blockade.

Authors:  Peter H Wang; Robert Washburn; Rohan Maniar; Michael Mu; Olivia Ringham; Radomir Kratchmarov; Brian S Henick; Steven L Reiner
Journal:  J Immunol       Date:  2022-07-29       Impact factor: 5.426

5.  Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade.

Authors:  Baolin Liu; Yuanyuan Zhang; Dongfang Wang; Xueda Hu; Zemin Zhang
Journal:  Nat Cancer       Date:  2022-09-22

Review 6.  'Stem-like' precursors are the fount to sustain persistent CD8+ T cell responses.

Authors:  Dietmar Zehn; Robert Thimme; Enrico Lugli; Gustavo Pereira de Almeida; Annette Oxenius
Journal:  Nat Immunol       Date:  2022-05-27       Impact factor: 31.250

7.  P2RX7 Enhances Tumor Control by CD8+ T Cells in Adoptive Cell Therapy.

Authors:  Kelsey M Wanhainen; Changwei Peng; Maggie H Zhou; Bruna de Gois Macedo; Stephen O'Flanagan; Tingyuan Yang; Ameeta Kelekar; Brandon J Burbach; Henrique Borges da Silva; Stephen C Jameson
Journal:  Cancer Immunol Res       Date:  2022-07-01       Impact factor: 12.020

8.  Lymphocytes in tumor-draining lymph nodes co-cultured with autologous tumor cells for adoptive cell therapy.

Authors:  Kazumi Okamura; Satoshi Nagayama; Tomohiro Tate; Hiu Ting Chan; Kazuma Kiyotani; Yusuke Nakamura
Journal:  J Transl Med       Date:  2022-05-23       Impact factor: 8.440

9.  Tumor-Specific CD4+ T Cells Restrain Established Metastatic Melanoma by Developing Into Cytotoxic CD4- T Cells.

Authors:  Qiao Liu; Lisha Wang; Huayu Lin; Zhiming Wang; Jialin Wu; Junyi Guo; Shuqiong Wen; Ling Ran; Zhengliang Yue; Xingxing Su; Qing Wu; Jianfang Tang; Zhirong Li; Li Hu; Lifan Xu; Lilin Ye; Qizhao Huang
Journal:  Front Immunol       Date:  2022-06-16       Impact factor: 8.786

Review 10.  T cell dysfunction in glioblastoma: a barrier and an opportunity for the development of successful immunotherapies.

Authors:  Josephina A Jansen; Antonio Omuro; Liliana E Lucca
Journal:  Curr Opin Neurol       Date:  2021-12-01       Impact factor: 5.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.